Dr. Sackner-Bernstein majored in electrical engineering at The University of Pennsylvania before earning an MD from Jefferson College and embarking on a career as a physician. He served on the faculty of Columbia University as a clinician, while performing clinical trials focused on heart failure. His expertise in drug development is based on these experiences, coupled with key roles at FDA and DARPA.

Throughout his career, Sackner-Bernstein earned a reputation for seeing in data what others could not. In 2002, he was the only person who foresaw that Natrecor, a drug purchased by J&J for $2.4B, should not be widely used for treatment of heart failure. After his data was published in JAMA, headlines about the drug’s risk appeared all over the world, and the drug was withdrawn from the market (see samples of media coverage below).

Sackner-Bernstein's mission of conquering Parkinson's started when his dear friend and mentor - beginning to suffer from worsening Parkinson's disease – insisted that Sackner-Bernstein could cure his disease.

Read more about Jonathan on LinkedIn, Wikipedia or the 2018 summary of his initial discoveries at: https://www.jsbmd.com/pd.